Anti Mineralocorticoid Therapy of Infection
First Claim
Patent Images
1. A pharmaceutical composition comprising at least one antimineralocorticoid compound or molecule.
0 Assignments
0 Petitions
Accused Products
Abstract
Antimineralocorticoid compounds are disclosed for use in the prophylaxis and therapy of viral infections, especially the retroviral infection by HIV. These compounds can be administered alone or in combination with conventional anti-viral agents or anti-sense mineralocorticoid Steroid ReceptorNA or DNA mutants of heat shock proteins.
-
Citations
87 Claims
- 1. A pharmaceutical composition comprising at least one antimineralocorticoid compound or molecule.
-
20-23. -23. (canceled)
-
26. (canceled)
-
30. (canceled)
-
32. (canceled)
-
34-65. -65. (canceled)
-
66. A method of preparing a vaccine comprising a virus, the method comprising the step of mutating or deleting from the viral genome nucleotides which encode for hydrophobic amino acid residues which cause binding of the virus to an aldosterone binding site on a mineralocorticoid steroid receptor, wherein the deletion or mutation prevents expression of the hydrophobic amino acid residues by the virus.
-
67. A method for the treatment and/or prophylaxis of a viral infection in a subject, the method comprising the step of:
administering a therapeutically effective amount of a pharmaceutical composition comprising at least one antimineralocorticoid compound to a the subject. - View Dependent Claims (68, 69, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)
-
70. (canceled)
-
71. (canceled)
-
72. (canceled)
-
84. A method for the treatment and/or prophylaxis of an AIDS related syndrome in a subject, the method comprising the step of:
administering a therapeutically effective amount of a pharmaceutical composition comprising at least one antimineralocorticoid compound to the subject. - View Dependent Claims (85)
-
86. A vaccine for immune clearance and immune memory cell development, the vaccine comprising a viral genome wherein the nucleotides which encode for the hydrophobic amino acid residues, which cause binding of the virus to an aldosterone binding site on a mineralocorticoid steroid receptor, have been deleted or mutated such that expression of the hydrophobic amino acid residues is prevented.
Specification